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            Anti-Circumsporozoite protein (CSP) monoclonal antibodies (mAbs) can neutralize Plasmodium 
sporozoites in vitro and passively transferred mAb against P. falciparum CSP can block liver 
invasion by sporozoites of a transgenic rodent parasite that expresses chimeric P. falciparum CSP 
(Pb-Pf), preventing infection in mice. Despite this, attempts at targeting CSP for a vaccine have 
fallen short of expectations, mainly since a single un-neutralized sporozoite can cause disease, 
necessitating sustained high-titer neutralizing antibodies which current vaccines have been unable 
to achieve.   
             Recently, David Baltimore’s laboratory developed adeno-associated virus type 8 (AAV8) 
platform that efficiently delivers pre-formed mAb genes in vivo and directs sustained, high-level 
mAb production. We have adopted this technology to express humanized mAbs against the N-
terminal region of the CSP protein of P. falciparum in mice. Mice developed high titer human 
IgG antibodies as early as one week post-transduction, and levels have remained constant for 
more than six weeks at 800 to 1000 µg of IgG/mL. Mice transduced with humanized CSP mAb 
5D5 (5D5-AAV) and challenged intravenously with 104 transgenic P.berghei parasite expressing 
complete P.falciparum CSP (Pb-PfCSP) sporozoites, exhibited a statistically significant decrease 
in liver parasite burden. Unexpectedly, no protection or delay to parasitemia was observed in 
mice challenged by infective Pb-PfCSP mosquito bites. 
             Neutralizing antibodies against the vector used in mAb delivery (Vectored Immunoprophylaxis; 
VIP) can inhibit expression of mAb. Neutralizing antibodies in the sera of Aotus monkeys 
previously transduced with AAV1, -7 and -8 vectors were detected using an AAV-luciferase 
assay. Based on the results of the assay, a correlation between high pre-existing neutralizing anti-
AAV antibodies titers and inhibition of AAV vectored mAb expression was noted. Our results 
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Malaria is an infectious disease that is caused by a single-celled protozoan of the genus 
Plasmodium. Despite tremendous efforts, malaria remains a significant global health problem 
with about 3.2 billion people still at risk from this parasitic disease1. The WHO estimates that 
there were 214 million cases of malaria in 2015 and 438 000 deaths1. The majority of these cases 
and deaths occur in Sub-Saharan Africa where there is a stable transmission of this disease all 
year round2. However, Latin America, Asia and to some extent the Middle East and Europe, are 
at risk as well1.  
The high prevalence of malaria and the disease burden it causes has made it a prime target for 
eradication programs. The current arsenal of tools against malaria include insecticides, bed nets, 
drainage of marshes and other sources of stagnant water and anti-malarial drugs like chloroquine 
and artemisinin. Chloroquine was an effective antimalarial drug until the 1950s, but now most 
malarial strains are resistant to this drug3. Artemisinin, another antimalarial drug was found to be 
extremely effective in treating people with malaria and was found to be effective against strains 
that were resistant to chloroquine. However, partial resistance to this antimalarial drug is now 
emerging 4,5. With the spread of anti-malarial drug-resistant Plasmodium strains that need for an 
effective vaccine against malaria is imminent. 
 
Plasmodium lifecycle  
 
Malaria belongs to the phylum apicomplexa, which also includes Babesia, Cryptosporidium, and 
Toxoplasma. The members of this phylum have complex lifecycle involving both asexual and 
sexual reproductive stages. The vector for Plasmodium is the female Anopheles mosquito, and it 
is here the sexual reproduction of the parasite occurs6. When a female Anopheles mosquito takes 
a blood meal from a human infected with malaria, the mosquito ingests gametocytes along with 
the blood meal6. Gametocytes are the sexual reproductive stage of the parasite, which are present 
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in the circulation of an infected human host6. External cues and drop in temperature in the 
mosquitoes promote the gametocytes to mature into haploid male and female gametes7. In the 
midgut, these haploid male and female gametes fuse to form diploid zygotes that develop into 
ookinetes6. The ookinete is motile and can transverse through the midgut wall of the mosquito till 
it reaches the basal lamina where it develops into the next lifecycle stage called the oocyst6. 
Oocyst are where the haploid sporozoites are produced and multiply to large numbers6. The 
sporozoites are elongated and reach a length of about 10 µm and have a diameter of about 1 µm, 
and this is the infective stage of the parasite life cycle8. When the sporozoites reach maturity, they 
are released from the oocyst into the hemocoel and circulate in the hemolymph of the mosquito. 
Some of these circulating sporozoites come in contact with the salivary glands, and 
approximately 15% of the circulating sporozoites will invade the salivary gland9. During the 
mosquito’s next blood meal, the salivary gland sporozoites are injected into the skin of the human 
host as it probes for blood10. A small portion of these sporozoites then find and invade a blood 
vessel11 and are carried to the liver by the blood flow. When reaching the liver, the sporozoites 
exit the blood circulation transverse across the sinusoid cell layer to infect hepatocytes12. Here, 
the sporozoites develop and mature into the exoerythrocytic schizont form in which thousands of 
hepatic merozoites are formed12. Rupture of these mature schizonts releases 2,000 to 40,000 
merozoites, and each of these merozoites can infect an erythrocyte cell in the host12.The 
merozoites in the erythrocytes develop into trophozoites and replicate in an asexual process called 
schizogony to form 10-14 merozoites10. The erythrocytes containing the merozoites rupture and 
the released merozoites invade new erythrocytes. The release of these merozoites from 
erythrocytes coincides with the cyclic fever which is characteristic of malaria13. A portion of the 
merozoites develop into the sexual stage of the parasite – gametocytes which are taken up by the 
vector as it takes a blood meal from the infected human host6. 
There are many members in the Plasmodium genus, but only five are known to infect humans. 
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These include Plasmodium falciparum, P. vivax, P.ovale, P.malariae and P.knowlesi. P.knowlesi 
was recently added to the list as a primate malaria but can cause infections in humans14. P. vivax 
and P.ovale, can cause relapse due to persistent liver forms of the parasite that can remain 
dormant for months to years6. P.falciparum is the predominant Plasmodium species in Sub-
Saharan African where the majority of deaths due to malaria occurs1. P.falciparum infect 
erythrocytes of all ages15 which leads to a higher parasite density in the blood of the host 
compared to those infected with the other Plasmodium species. The high levels of parasitemia 
during P.falciparum infection can lead to severe anemia due to the rupture of the infected 
erythrocytes6. P.falciparum infected erythrocytes are also thought to have the ability to adhere to 
the surrounding vasculature to prevent splenic disruption. The adherence of the parasite-infected 
cells can lead to the blockage of blood vessels and the blockage of the brain vasculature is known 
as cerebral malaria6. Cerebral malaria and severe anemia are clinical manifestations of severe 
malaria which is common among P.falciparum infected individuals, especially children under the 
age of five years6.  Most current vaccine development efforts are targeted against P.falciparum 
which causes the most deaths compared to the other human Plasmodium species. 
 
Pre-erythrocytic vaccine rationale and vaccines 
 
Current malaria vaccine development efforts have been focused on three different stages of the 
Plasmodium life cycle: the pre-erythrocytic stage that consists of the sporozoites in the skin and 
the liver stage, the erythrocytic phase that involves the invasion and asexual reproduction of the 
parasite within red blood cells (RBCs), and finally, the transmission stage that involves 
gametocyte uptake and further development of the parasite within the mosquito (figure 1)16. In 
comparison to the other stages, vaccines directed against the pre-erythrocytic phase of the parasite 
can prevent both the manifestation of disease and the transmission of the parasite by inducing an 
immune response against the sporozoites and/or the liver stage that will neutralize sporozoites 
and prevent invasion of hepatocytes and/or the induction of CD8+ T cells that can recognize and 
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kill infected hepatocytes17–19. The number of sporozoites transmitted by a mosquito into the host 
is around 10 - 120 sporozoites, based on a 3 minute feeding time20,21 and a vaccine that can 
neutralize all these injected sporozoites can lead to sterile immunity.  
Vaccines that are under current development mainly target the circumsporozoite protein (CSP), 
thrombospondin-related adhesion protein (TRAP) which is essential for sporozoite motility and 
invasion22,23 and liver-stage antigen (LSA) which plays a role in the differentiation of the parasite 
in the liver24,25. The main goal of a vaccine is to provide sterile immunity against the disease and 
in the case of malaria, this has been achieved by inoculation with radiation-attenuated 
sporozoites19,26,27. To achieve sterile immunity by the use of irradiated sporozoites requires 
individuals to be bitten by roughly 1000 irradiated infectious mosquitoes or receive five 
intravenous injections (i.v) of irradiated sporozoites19,28. These methods of inoculation are tedious, 
require skilled labor and the sporozoites need to be maintained in cold-chain storage to ensure 
their vitality. These limitations and other logistical issues have made this vaccine impractical for 
global use.  
Studies conducted on immune responses induced by irradiated sporozoites have helped elucidate 
the mechanism by which the immune response provides protection. The majority of the research 
has shown that the predominant immune response in irradiated sporozoite vaccinated volunteers 
was antibodies directed against CSP29. CSP covers the surface of sporozoites and is implicated in 
sporozoite development, adhesion, and migration 30–33. CSP consists of three main regions – a 
central repeat domain bound by a C-Terminal region containing a type I thrombospondin repeat 
(TSR) motif on one side and an N-terminal portion containing a conserved proteolytic cleavage 
site on the opposite side6. Studies have shown that the majority of anti-CSP antibodies recognized 
the central (NANP)3 region in P.falciparum CSP
34, a B cell epitope that varies among 
Plasmodium species but is highly conserved in isolates of the same species from different 
geographical regions 35. Passive transfer of monoclonal antibodies that recognize this B cell 
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epitope have shown to be protective against the disease in both mouse and non-human primate 
(NHP) models36. However, sporozoites do not spend a lot of time in the skin (1 to 2 hrs., though 
some leave within minutes)37 and blood before invading the liver, limiting the interaction between 
the neutralizing antibodies and the sporozoites. To overcome this issue, a sustained high level of 
anti-CSP specific antibodies is required for a solely humoral-based protective immune response.  
In July 2015, a pre-erythrocytic malaria vaccine called RTS, S/AS01 was approved by the 
European Medicines Agency (EMA) becoming the first vaccine against malaria or any parasitic 
disease to be licensed. EMA has recommended the vaccine to be used in young children (6 weeks 
to 17 months) in areas where P.falciparum is prevalent38. RTS, S malaria vaccine was developed 
by GlaxoSmithKline (GSK) in collaboration with Walter Reed Army Institute for Research and 
PATH Malaria Vaccine Initiative (MVI). The vaccine consists of a hepatitis B surface antigen 
(HBsAg) fused to 19 copies of the central repeat region and C-terminal flanking region of P. 
falciparum mixed with unfused HBsAg39.This recombinant CSP consists of both B and T cell 
epitopes capable of inducing both neutralizing antibodies and cell-mediated immunity against the 
sporozoite and the liver stage39. Preliminary evaluation of the RTS, S vaccine showed that the 
addition of a novel oil-in-water adjuvant, ASO1, which was later optimized to the 
Monophosphoryl lipid A (MPL) and QS-21 bearing adjuvant ASO2 increased the antibody 
response to the vaccine40,41. A phase III clinical trial for RTS, S was conducted in 11 different 
sites in Africa where children (5–17 months) and infants (6–12 weeks) were given three doses of 
the vaccine in a randomized manner42. Vaccine efficacy against clinical malaria in children 20 
months after dose one was found to be was 45%. The vaccine efficacy was found to be  46% in 
children, 18 months after dose 3 was administered42. The vaccine efficacy against malaria 
hospitalization, severe malaria and all-cause hospitalization in children was found to be 41%, 
34%, and 19% respectively42. In infants (6–12 weeks), the vaccine efficacy was found to lower 
(27%) and did not show significant protection against malaria hospitalization, severe malaria, and 
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all-cause hospitalization42. Vaccine efficacy was found to wane over time as well42. The addition 
of a booster dose increased the efficacy of the vaccine in both children and infants43. RTS, S has a 
low vaccine efficacy but is still capable of averting some clinical malaria and severe malaria 
cases and can help reduce the burden of disease in Africa. It has also paved the way for the 
development of second-generation malaria vaccines.  
An alternate method of vaccination is the use of viral vectors to deliver genes into a host. An 
adeno-associated virus vectored Immunoprophylaxis (VIP) vaccine expressing neutralizing 
antibody 2A10 or 2C11 was developed and tested in the Ketner lab. 2A10, and 2C11 are anti-P. 
falciparum CSP monoclonal antibodies that recognize the central NANP repeat region in P. 
falciparum CSP44,45 and are protective if passively transferred to naive mice. 2A10-AVV or 
2C11-AVV (1x1011 genome copies) were injected intramuscularly (i.m) into the cranial thigh 
muscle in mice and these mice expressed human Immunoglobulin G (hIgG)  levels between 100 
to 500 μg/mL in serum (some mice had hIgG levels up to 1200 μg/mL in their serum) which was 
sustained until the end of the study (52 weeks)45. 2A10-AAV and 2C11-AVV transduced mice 
showed a significant decrease in liver parasite burden when challenged with transgenic P. berghei 
sporozoites containing a chimeric CSP gene bearing the P. falciparum CSP central repeat (Pb/Pf ), 
injected intravenously (1.0x104- 2x104 sporozoites per mouse)45. 2A10-AAV and 2C11-AVV 
transduced mice were also challenged by infected mosquito bites and 60% of 2A10-AAV and 
30% of 2C11-AAV transduced mice showed sterile protection and the other mice in these groups 
showed delayed parasitemia compared to the control group45. All mice transduced by 2A10-AAV 
expressing hIgG levels > 1000 μg/mL in their serum showed sterile protection against disease45. 
This alternative method has showed promise and further studies in NHP models and the use of 





Adeno-associated Virus  
AAV is a small (~25nm) Single stranded DNA virus in the parvovirus family that belongs to 
the genus Dependovirus. AAV is a nonenveloped virus, and its capsid is composed of three 
proteins-VP1, VP2 and VP3 arranged in T=1 icosahedral symmetry. Each Capsid consists of 
60 protein subunits and these proteins VP1-3, are present in 1:1:10 proportion46. The Core of 
each VP has a conserved structure that consists of an eight stranded β-barrel motifs (βB to 
βI) and an α-helix (αA). AAV have long loop insertions that connect the core β-barrel strands 
and these loops cluster at the surface forming nine conformational variable regions (VRI-
VRIX) that lead to local variations in the capsid surface46,47. These different conformations 
of the variable regions are thought to influences the tissue transduction efficiency, cellular 
tropism and antigenic reactivity between the various AAV serotypes47–50. 
The AAV single stranded DNA genome is around 4.7 kb and is flanked by an inverted terminal 
repeat (ITR) sequences of about 145 nucleotides on either side51.The ITRs arrange into a T-
shaped, base-paired hairpin structure which contain important cis-elements for viral encapsulation 
and replication52. They also contains cis-elements required for viral genome integration and 
rescue from host chromosomal DNA53. The genome consists of two genes, the rep (transcription 
regulated by promoters p5 and p19) that encodes four non-structural proteins (Rep-78, -52, -68 
and -40) formed by alternative mRNA splicing, crucial for viral replication, and the cap gene 
(transcription regulated by promotor p40) that encodes the three structural proteins (VP1-3) that 
constitute the AAV capsid. Rep78 and Rep68 play a role in the regulation of viral and cellular 
promotors, viral replication, site-specific integration and rescue of integrated AAV genome54–60. 
Rep52 and Rep40, are important for accumulation of viral DNA for packaging into new AAV 
particles61. All four Rep proteins have helicase and ATPase activity62,63. 
The different AAVs are known to bind to a variety of cell receptors on their target cell in the host. 
AVV2,-3 and -6 bind heparan sulfate proteoglycan receptors on the cell, while AAV1, -4, -5 and -
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6 bind sialic acid and AAV9 binds galactose64. AAV2 is also known to use fibroblast growth 
factor receptor 165. AAV serotype 8 which was isolated in rhesus macaques uses the 37/67 KD 
Laminin receptor (LamR) to help bind to its target cells66. LamR binds AAV3, -9 and -2 as 
well66.After binding to their receptor, AAV2 is taken into the target cell by clathrin-mediated 
endocytosis which is aided by αvβ5 integrin67. The virus is eventually released into the cytosol and 
penetrates into the nucleus through the nuclear pore complex (NPC)68. Inside the nucleus, the 
virus can go into a latent state or through a lytic cycle depending on the presence or absence 
helper viruses - adenovirus or herpes simplex virus. In the presence of helper virus function, 
AAV replication is productive and consists of three main steps: the conversion of the single 
stranded viral DNA genome into a double stranded template for transcription, unidirectional 
strand-displacement replication and terminal resolution of self-annealed ITRs69. Transcription of 
the rep genes occur first as it plays a significant role in both positive (in the presence of helper 
effects) and negative regulation of transcription54. Helper virus co-infection activates promoters 
p5 and p19 which leads to the transcription of Rep68, -78, -52 and -40 and after Rep proteins are 
transcribed, extensive DNA replication occurs55,56,70,71. AAV goes through unidirectional strand 
displacement replication for the replication of its DNA and the ITRs on either sides of the DNA 
have motifs – the Rep binding site (RBS) and Terminal resolution site (TRS) that serve as the 
viral origin of replication72,73. The ITRs have the ability to self-anneal and provide a base-paired 3’ 
hydroxyl group for unidirectional DNA synthesis. The host replication machinery including 
polymerase δ along with some components from the helper virus mediates DNA synthesis74–76. 
After DNA synthesis, terminal resolution occurs to replicate the self-annealed ITR. This process 
is mediated by the Rep proteins that bind to the RBS motif within the ITR and leads to a site- and 
strand-specific nick at the TRS that regenerates a 3’ hydroxyl end77. The newly synthesized 3’ 
hydroxyl end enables replication through the viral ITR77. At the end of the replication cycle, there 
are two possible products - a single-stranded full-length AAV displacement product and a double-
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stranded full-length AAV genome. The roles of these products are still unknown, but it is thought 
that the single-stranded AAV genome might serve as a template for further replication and the 
double-stranded replication product may act as a template for genome packaging69. 
In the absence of helper virus factors, there is a limited expression of Rep68/78 which leads to the 
repression of AAV genome, inhibition of DNA replication and integration of viral DNA into the 
host genome54. The integrated AAV genome can be rescued by coinfection of a latently infected 
cell with a helper virus78. Integration of viral DNA into host genome can result in upregulation of 
genes and tumorigenesis which is a safety concern. Many in vitro studies have been conducted to 
investigate the mechanism and biological effects of AAV DNA integration into the host genome. 
Wild type (WT) AAV was found to integrate most frequently in a site-specific manner on the 
chromosome 19q13.42, also known as AAVS179,80. This site-specific integration is rep 
dependent81 which is not present in rAAV used for gene therapy and other therapeutics. Other 
integration hotspots include sites on chromosome 5p13.3 (AAVS2) and chromosome 3p24.3 
(AAVS3)82. In contrast, In vivo studies have shown the WT AAV DNA integrates at a low 
frequency and majority of the DNA exists as double stranded episomes in human tissue83. rAAV 
lacks many components of WT AAV, like the Rep proteins but are still found to integrate into the 
host genome at low frequency which can potentially lead to genotoxicity84. The results of a study 
conducted in mice showed the presence of integrated AAV vector proviruses in four different 
tumors from four different mice. All these integrated AAVs were mapped to a 6-kb region of 
chromosome 12 (AAV-HCC locus), and no AAV DNA was found in the surrounding normal 
tissue suggesting that integration of AAV vector may lead to cancer in certain situation including 
the age of the mice and type of AAV vector used85. A recent study to test the safety and site-
specific integration of rAAV vectors was done using the EMA licensed AAV1-LPLS447X vector 
which was developed for the treatment of lipoprotein lipase deficiency (LPLD). Tissue from 
human and mice subjects that had previously received on or more doses of AAV1-LPLS447X 
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administered i.m was used to map the vector integration sites in the host genome. In the human 
samples, two vector integration hotspots- one within the PCBD2 gene and the other near the gene 
OR4F29 in the nuclear genome were identified86. However, the majority of the vector integration 
sites were in the mitochondrial DNA (mtDNA) compared to the nuclear genome86. The hotspots 
for vector integration in mice were found to be near the Col19a1 gene (composed of mtDNA-
homologous sequences), the muscle-specific gene Ttn and in the Myh gene in the nuclear 
genome86. Specific mtDNA enrichment combined with direct sequencing performed on one 
mouse sample showed that majority of the vector integration sites (12 out of 20) occurred within 
a nuclear mitochondrial DNA region (Similar sequences present in both mitochondrial and 
nuclear genomes )86. No significant vector genome integration was noted in the AAVS1 locus 
(common integration site of WT AAV) or the AAV-HCC locus (implicated in AAV integration–
mediated formation of hepatocellular carcinoma)86.These results indicate that use of rAAV vector 
is safe and could be used to treat of mitochondrial disorders by gene therapy.  There are still some 
concerns about using AAV vectors in humans and it is an active field of study, and that is 
continuing to grow as rAAV use increases. 
Adeno – associated virus vectors in gene therapy 
 
Adeno-associated virus (AAV) was first discovered in 1965 87 and with the understanding of the 
basic biology of AAV and its ability to infect a wide variety of tissues have promoted the 
development of recombinant adeno-associated virus vectors (rAAV) that are now being used in 
gene therapy frequently. The extensive use of rAAV in gene therapy is due to its low 
immunogenicity, lack of pathogenicity of the wild-type (WT) virus, ability to transduce a broad 
range of dividing and non-dividing cell types and its ability to maintain long-term gene 
expression after transduction. Around twelve human AAV serotypes and more than a hundred 
NPH AAV serotypes have been identified88. AAV serotype 2 (AAV2) was the first AAV 
serotypes to discovered and characterized. For this reason, rAAV2 was used as a vector to treat 
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hemophilia B, cystic fibrosis, Parkinson’s disease, rheumatoid arthritis, age-related macular 
degeneration, Batten disease, Leber’s congenital amaurosis and Canavan’s disease89. Clinical 
efficacy of AAV based gene therapy was first noted when patients suffering from Leber’s 
congenital amaurosis, an autosomal recessive disease that causes congenital blindness, were 
treated with rAAV2-RPE65 and showed improved vision and sensitivity to light for four to 
six years90–93. Parkinson’s and congenital aromatic L-amino acid decarboxylase (AADC) 
deficiency were treated with the rAAV2-AADC vector; the results indicated improved gross 
motor development in both trials94,95. 
An important realization in AAV-mediated gene therapy was that the different AAV 
serotypes have different transduction efficiencies for certain tissues. Transduction with 
AAV8 vectors in skeletal muscles and cardiac muscles, results in systemic gene transfer in 
these tissues as AAV8 can efficiently cross the blood barrier compared to the other AAV 
serotypes in mice and hamsters96. AAV1 was found to have a higher transduction efficiency 
for skeletal muscles than AAV2 97. AAV6 and AAV5 transduce murine airway epithelial 
more efficiently than the other AAV serotypes98. The understanding of the various tissue 
tropisms of the different AAV serotypes and the formation of hybrid vectors with AAV2 
replication genes and capsids of other serotypes have led to the development of more 
efficient vectors99. Pseudotyped (foreign DNA encapsulated by viral capsid proteins) AAV8 
vector expressing factor IX has some success in treating hemophilia B100. rAAV1-lipoprotein 
lipase (LPL) administered i.m was found to decrease pancreatitis and serum cholesterol 
levels in patients suffering from lipoprotein lipase deficiency101. In 2012, rAAV1-LPL was 
licensed in Europe102 and it opened up opportunities for the continued study of AAV as a tool 






Pre-existing immunity  
 
rAAV vector mediated gene transfer has shown promise as a therapeutic for many diseases. An 
obstacle to this treatment approach is the presence of pre-existing neutralizing anti-AAV 
antibodies and acquired antibodies generated after treatment with rAAVs that can reduce or 
inhibit the efficiency of these therapeutics, especially if the vector needs to administered 
repeatedly103,104. Around 30-80% of the world’s population is estimated to be seropositive for 
anti-AAV antibodies against AAV1 and -2, with anti-AAV2 being the most prevalent105. A study 
conducted in France with serum samples of small human cohort concluded that the prevalence of 
neutralizing antibodies against AAV5, -6 and -9 was around 50 % and AAV8 had a 
seroprevalence of less than 40%106. Non-neutralizing antibodies that are capable of binding AAV 
can also inhibit vector transduction by activating the immune system and clearing the vector from 
the host 107. The development of this humoral response to AAV is thought to occur early in life 
around the age of two as a consequence of WT AAV exposure 108,109. Additionally, newborn 
babies have been found to have maternal anti-AAV antibodies that decrease few months after 
birth but increase again 108,109. These studies show that the time frame where individuals are naive 
to anti-AAV is narrow, making it difficult to administer AAV vectored therapeutics. 
Humoral response mounted against WT AAV leads to the production of all four IgG subclasses 
with IgG1 being predominant106,110,111. Lower IgG2 levels were also present in the anti-AAV 
specific antibody response and the highest levels of IgG2 were found against AAV8106. IgG3 and 
IgG4 levels were low and variable with AAV6 inducing the highest IgG3 response106. Another 
problem imposed by anti-AAV antibodies is their ability to cross-react with a broad range of 
AAV serotypes106. This is mostly due the high degree of amino acid conservation among AAVs112. 
Characterization of the immune response against AAV can help in understanding and overcoming 
the problem presented by this immune response against rAAV vectored gene transfer therapeutics. 
13 
 
Most Studies use Enzyme-linked Immunosorbent assay (ELISA) to determine the anti-AAV 
antibody titers in serum. The disadvantage of using this test to detect antibody titers is that it 
cannot distinguish between neutralizing and non-neutralizing antibodies. Cell based assays have 
been developed to the better estimate the neutralizing activity of anti-AAV antibodies in a host. 
The development of more sensitive tests can be used to detect naive individuals for AAV 
vectored therapeutics or help decide which AAV serotype should be used as a vector. Other 
methods to overcome the presence of neutralizing anti-AAV antibodies include the development 
of novel, artificial AAV vectors113, plasmapheresis114, transient immunosuppression115,116, 
delivery of the vector with isolated perfusion and saline flushing117 and modulation of antibody 

















          Figure 1: Stages of the malarial life cycle that are vaccine targets. 
Pre-erythrocytic vaccines targeting antigens expressed on sporozoites or infected 
hepatocytes can prevent both disease and transmission. Blood-stage vaccines targeting 
antigens expressed on merozoites and infected red blood cells work to reduce disease 
severity and transmission blocking vaccines targeting either gametocytes or developmental 
stages within the mosquito prevent transmission of the Plasmodium parasite. 
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Materials and Methods 
 
Construction and Cloning of VIP plasmids 
 
To express b12 (anti-HIV-1 gp120)  and 2A10 (anti-P. falciparum CSP) antibodies in mice, the 
DNA sequences of the variable regions of these antibodies were synthesized from published 
sequences119 and cloned into the VIP expression vector as previously described (Figure 2) 120,121. 
This was done in Dr. David Baltimore’s laboratory at California Institute of Technology by Dr. 
Alex Balazs and tested further by Dr. Cailin Deal in Dr. Gary Ketner’s laboratory at Johns 
Hopkins Bloomberg school of Public Health. These previously studied VIP expression vector 
plasmids were used in this study as controls. 
 5D5, an anti-P.falciparum CSP monoclonal antibody that specifically binds to a linear epitope 
EDNEKLRKPKH near the proteolytic cleavage site in the N-terminus region of P.falciparum 
3D7 CSP (Figure 3)122 was produced by Leidos Inc and the DNA sequences of the variable 
regions of 5D5 mAb were provided by Aragen Biosciences Inc. To test the effects of 5D5 mAb 
against transgenic P. berghei expressing complete P. falciparum CSP using VIP system, the 
variable region DNA sequences of 5D5 mAb were cloned into the previously characterized 2A10 
VIP expression vector, replacing the 2A10 mAb variable DNA sequences. The 5D5 mAb variable 
light (VL) and heavy (VH) chain DNA sequences were compared to that of 2A10 in the VIP 
expression vector, to determine the insertion site for the 5D5 mAb sequence in the VIP 
expression vector using a software called DNA Strider. 5D5 VL and VH chain insert sequences 
were synthesized by GeneArt. The synthesized 5D5 VH chain insert sequence was flanked by 
built-in restriction sites for Not1 and Age1, and the synthesized 5D5 VL chain insert sequence was 
flanked by built-in restriction sites for Nsi1 and PuvII. Restriction digestion was carried out with 
20 μg of plasmid DNA containing the 5D5 VH insert sequence and 20 μg of plasmid DNA 
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containing the 5D5 VL chain insert sequence. These reactions were incubated at 37°C for 2 hours 
(h) and run on a 1% agarose gel containing 0.5 μg/mL ethidium bromide at 50mA with a 100bp 
ladder (Invitrogen).  The QIAquick Gel Extraction Kit (Qiagen) was used to extract and purify 
the 5D5 VH and VL insert DNA from the agarose gel. The amount of extracted insert DNA was 
determined by nanodrop spectrometer. In two separate reactions, 20 μg of backbone 2A10 VIP 
plasmid was digested using Not1 and Age1 (to remove 2A10 VH sequence from the VIP plasmid) 
and Nsi1 and PuvII (to remove 2A10 VL sequence from the VIP plasmid). These reactions were 
incubated at 37°C for 2h. 5µl sample of each reaction was run on a 1% agarose gel containing 0.5 
μg/mL ethidium bromide at 50mA with a 100bp ladder. The restriction enzymes in the two 
reactions were heat-inactivated by heating the reactions at 65°C for 20 minutes (mins). The 
digested vector DNA was dephosphorylated by adding Shrimp Alkaline Phosphatase (New 
England Biolabs) and incubating at 37°C for 1h.The Shrimp Alkaline Phosphatase was heat 
inactivated by heating the reactions at 65°C for 5 mins. The digested 2A10 VIP vector DNA 
without 2A10 VH chain and the 5D5 VH insert DNA ligated using T4 ligase (New England 
Biolabs) to form the 5D5H-2A10 plasmid. The Vector to insert DNA ratio in the ligation reaction 
was 1:4 and was incubated overnight at 16°C123. The T4 ligase was heat inactivated by heating 
the reaction at 65°C for 10 mins. The same ligation process was followed for the digested 2A10 
VIP vector DNA without 2A10 VL chain and 5D5 VL insert DNA to form the 5D5L-2A10 
plasmid. The new plasmids were transformed into DH5α competent cells (MAX Efficiency 
DH5α competent cells ThermoFisher Scientific) and plated on Luria Broth (LB) plates containing 
60µg/mL of ampicillin and incubated at 37°C for 24h 123.Selected colonies were grown in LB 
broth containing 60µg/mL of ampicillin for 24hrs at 37°C, and plasmid DNA was extracted from 
these cultures using Qiagen Plasmid plus kit. Restriction Digestion and sequencing were done to 
confirm the correct insertion of 5D5 VH and 5D5 VL sequences in the 5D5H-2A10 and the 5D5L-
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2A10 plasmids respectively. 5D5H-2A10 plasmid was used as the backbone to construct the 5D5 
VIP plasmid containing both 5D5 VH and VL chain sequences. The 5D5H-2A10 plasmid digested 
with restriction enzymes Nsi1 and PuvII to remove the 2A10 VL chain sequence and the 5D5 VL 
insert DNA was inserted into this plasmid using the same method as previously mentioned. 
Restriction Digestion and sequencing were done to confirm the correct insertion of 5D5 VH and 
VL chain in the newly formed 5D5 VIP plasmid. All plasmid stocks and DNA were stored in the -
80. 
Validation of the Functionality of the 5D5 VIP plasmid  
 
To validate the functional activity of the 5D5 VIP plasmid, 293T cells (human embryonic kidney 
cells) were grown in modified Minimum Essential Media (MEM) containing 10% Fetal Bovine 
serum (FBS), 1% Penicillin-Streptomycin mixture (P/S) and 1% L-glutamine (L-Glu) in a 12 well 
tissue culture plate (Corning), until the cells reached 70-80% confluency. 293T cells were 
transfected with 1µg of 2A10 VIP plasmid, 5D5 VIP plasmid, 5D5H-2A10 plasmid and 5D5L-
2A10 plasmid DNA in duplicates using transfection reagent BioT (Bioland Scientific). Two wells 
were not transfected with DNA and were used as a negative control. 48h post-transfection, 50 μL 
of supernatant was pipetted out of each well and quantified for total human IgG production by 
ELISA120. 
Production and purification of AAV VIP virus  
 
The method followed to prepare AAV vector virus expressing 5D5 mAb or luciferase 
has been previously described120.Three days before transfection, four 15 cm plates 
were seeded with 3.75 × 106  293T cells each in 25 mL of  modified MEM and these 
plates were maintained in a 5% CO2 incubator at 37 °C.2 or more hours before 
transfection, the media in the plates were removed and 15mL of  Dulbecco’s 
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Modified essential media (DMEM) containing 10%FBS,1%P/S and 1% L-Glu (media 
will be referred to as D10) was added. 197μg of pAAV DNA, 98.4μg of helper vectors 
pHELP DNA (Applied Viromics) and 24.6μg of 5D5 VIP plasmid DNA (or luciferase 
for luciferase assay) were mixed together in a 50mL tube. To 16mL of DMEM (no 
serum), 240µl BioT was added and vortexed. The DNA was mixed with the BioT 
DMEM mixture, vortexed and incubated for 5mins at room temperature. 4mL of this 
reaction was added to each 15cm plate containing 293T cells. The supernatant was 
collected at five time points -36, 48, 72, 96 and 120 h, passed through a 0.22µm filter 
(Millipore) and stored in 4°C. 15mL of fresh D10 media was added to the plates 
every time the supernatant was collected. The collected supernatant was split into 
two glass bottles (~150mL each) and 37.5 mL of 5×PEG solution (40% polyethylene 
glycol, 2.5 M NaCl) was added to each bottle and the virus was allowed to precipitate 
on ice for 24h in 4°C. The solution was centrifuged (Sorvall RC5C centrifuge) at 5000 
RPM for 30mins at 4°C and the supernatant was removed. The pellets were re-
suspended using 1.37 g/mL caesium chloride solution and the solution was 
transferred to two Sorvall quick seal tubes. The solution was centrifuged (Sorvall 
WX ultracentrifuge) at 60,000 RPM for 24h at 20°C. Fractions of the centrifuged 
solution were collected (100-150µl per well) in a 96 well flat bottom plate and the 
refractive index of these fraction were determined using a refractometer. Fraction 
with a refractive index between 1.3755 and 1.3655 were combined and the final 
volume was made up to 15mL by adding Test Formulation Buffer 2 (TFB2, 100 mM 
sodium citrate, 10 mM Tris pH 8). The solution was pipetted on to a 100 kDa MWCO 
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centrifugal filter (Millipore) and centrifuged at 3000 RPM (Sorvall legend RT series 
centrifuge) at 4°C for 30-45 mins or till the retentate was below the 1mL mark. The 
virus was washed three times by adding 15mL of TFB2 each time to the filter and 
repeated centrifugation. The membranes were washed with 300µl of TFB2 and the 
final retentate was aliquoted and stored at −80 °C. 
AAV quantification  
The quantification AAV vectors has been previously described 120.The unknown AAV virus and 
standard sample (AAV8 virus expressing b12 mAb-1x1012GC/mL) were diluted tenfold in DNase 
buffer and 10 units of DNase l (Roche) was added to each sample. The samples were incubated at 
37°C for 30 mins. The Unknown AAV samples were diluted in DPEC treated water to 1:1000, 
1:10000 and 1:100000.The Standard curve was created by diluting the standard sample four-fold 
in DPEC treated water from 2x1010 GC/mL to 0 GC/mL.  A PCR mix containing 8.2µL of SYBR 
green, 2µL of DPEC treated water and 0.33µL of forward and reverse primers (5′ CMV: 
AACGCCAATAGGGACTTTCC and 3′ CMV: GGGCGTACTTGGCATATGAT or the 
luciferase transgene (5′ Luc: ACGTGCAAAAGAAGCTACCG and 3′ Luc: 
AATGGGAAGTCACGAAGGTG) per sample was prepared. 10µl of PCR mix and 5µL of 
sample were added to the 96 well PCR plate. The samples were run in duplicates in the 
MicroAmp Fast Optical 96-Well Reaction Plate. The amount Virus in the samples were 
quantified using a quantitative PCR (Applied Biosystems One Step Plus qPCR) with the program: 
one cycle of 50 °C for 2 mins, one cycle of 95 °C for 10 min, 40 cycles of 95 °C for 15 seconds (s) 
and 60 °C for 60s. 




Aliquots of previously titered viruses were thawed on ice and diluted in TFB2 to achieve the 
predetermined dose of 1x1011 genome copies in a 50 µL volume. Inbred 3-to 4 week old 
C57BL/6 (Jackson Laboratories) female mice, in groups of four or ten, were given a single 50 µL 
intramuscular (i.m.) injection into the cranial thigh muscle with a 29G needle. At various times 
after vector administration, blood was collected from the cheek vein into serum separator tubes 
(BD). Tubes were spun for 10 minutes at 5,000 RPM to separate sera from red blood cells. Sera 
was collected and stored at -80°C. 
Quantification of antibody production by ELISA 
 
For the detection of total human IgG, ELISA plates were coated with 0.1µg per 100µL per well 
of goat anti- human IgG-Fc antibody (Bethyl) overnight 120. Plates were washed three times with 
TBS containing 0.1% Tween20 (TBS-T) and three times with TBS followed by blocking with 
200µL 1% BSA (Sigma) in TBS (TBS-1% BSA) per well for 1h. Samples were serially diluted 
three-fold in TBS-1% BSA starting at 1:1500. 100µL of each sample dilution was added to the 
plate and incubated for 1h at room temperature (RT). Plates were washed as above and incubated 
with 100µL per well TBS-1% BSA diluted HRP- conjugated goat anti-human kappa light chain 
antibody (1:10,000; Bethyl) for 1h at RT. Plates were washed a final time and 100µL of ABTS 
Peroxidase Substrate System (KPL) was added per well. The plate was incubated in the dark for 
15 minutes at RT. The reaction was stopped by adding 100µL 2M sulphuric acid per well. Using 
Human Reference Serum (Bethyl), a standard curve was generated and mouse pre-bleed sera 
were used to establish background. Plates were read at a wavelength of 450nm using a Molecular 
Devices Emax microplate reader. 
For the detection of anti-CSP antibodies, plates were coated with 0.05µg per well of P. 
falciparum CSP purified from MR-272 plasmid (Malaria Reference and Research Resource MR-
272) overnight 124. All subsequent steps are described above except a standard curve was not 
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utilized. The positive control used was Purified 2A10 and the dilution at which the optical density 
value was two times greater than the blank was reported as the endpoint titer. 
Parasite 
 
Transgenic murine Plasmodium berghei sporozoites expressing the complete human P. 
falciparum CSP (Pb-PfCSP) were used in all the experiments. The transgenic parasite was 
developed by Dr. Diego A. Espinosa in Zavala laboratory. The parasite was ordered through the 
parasite core at Johns Hopkins Bloomberg School of Public Health. 
 
Pb/Pf CSP Challenge 
 
C57BL/6 mice were used for the experiments since they have been shown to be highly 
susceptible to sporozoite challenge 125. Infected Anopheles stephensi mosquitoes were 
anesthetized on ice and transferred to a petri dish containing 70% ethanol for 30s. The 
mosquitoes were then transferred to a plate filled with Hank’s balanced salt solution (HBSS, 
invitrogen) containing 1% mouse serum. The salivary glands were dissected out under a light 
microscope using a 25G needle. The dissected salivary glands were transferred to an Eppendorf 
tube along with the dissection media and kept on ice. The salivary glands were crushed and the 
amount of sporozoites present in the supernatant was counted using a hemocytometer.  Mice 
were challenged intravenously with 1.0 x104 transgenic Pb-PfCSP parasites126. Approximately 
38.5h later, mice were euthanized to assess parasite burden in livers. Whole livers were 
homogenized in denaturing solution (4m Guanidine Thiocyanate, 25mM Sodium Citrate pH 7, 
0.5%N lauryl sarcosine and β-mercaptoethanol), and RNA was extracted as previously 
described127,128. The total RNA in the samples were determined by nanodrop spectrometer and 
diluted to a final concentration of 100ng/mL for cDNA synthesis. After cDNA synthesis, 
parasite loads were determined by qPCR for P. berghei 18S rRNA129 and mouse GAPDH was 
used as an internal control. 
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For the assessment of sterile protection, Anopheles stephensi mosquitoes infected with Pb-PfCSP 
parasites were starved overnight. Mice were anesthetized with 300 to 350 µL of 2% avertin and 
were subjected to feeding from 5-8 mosquitoes for 10 minutes. The number of mosquitoes that 
fed on each mouse was noted, based on the presence of blood in the midgut after dissection.  
Starting from day 4, blood smears were made daily until day 14 by nicking the tail of each mouse 
and collecting blood, and these smears were observed under a microscope for blood stage 
parasites. Smears were fixed with methanol before staining with a 10% Giemsa stain solution 
(Sigma-Aldrich) for 20 mins. The slides were observed under 100x magnification under a light 
microscope. The day post infection that blood stage parasitemia was evident was recorded as the 
day of patency. After confirmation of parasitemia, mice were euthanized.  Mice were considered 
to be sterilely protected if there was no evidence of parasitemia by day 14. 
 
Luciferase assay to detect neutralizing antibodies against AAV 
 
The detection of neutralizing antibodies against AAV was done as previously described130 with 
some modifications. 2V6.11 cells131 were diluted to 2 x105 cells/mL in DMEM media containing 
10% heat inactivated FBS, 1% P/S and without phenol red. Ponasterone A was added to the cell 
containing media at a final concentration of 1µg/mL. 100µL of this solution was added per well 
into a black 96 well flat bottom tissue culture plate (UltraCruz) and incubated overnight in a 37°C, 
5% CO2 incubator. Serum samples were diluted 1:3.16 times in heat inactivated FBS. Previously 
titered viruses expressing luciferase were diluted in TFB2 to a concentration of 5 x109 GC/mL. 
20µL of the diluted serum samples were mixed with 20µL of the diluted virus and incubated for 
1h in a 37°C, 5% CO2 incubator. As a negative control or minimum neutralization control, 20µL 
of the diluted virus was added to 20µL of FBS and incubated along with the other samples. 7.5µL 
of each sample and control was added per well to the tissue culture containing the 2V6.11 cells 
and incubated overnight in a 37°C, 5% CO2 incubator. Samples were added in duplicates or 
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triplicates.100 µL of Bright-Glo luciferase assay system (Promega) was added per well in the 
tissue culture plate and allowed to sit at RT for 3 mins.  Luminescence of each sample was read 
using IVIS spectrum in vivo imaging system. The first dilution to show 90% or above 




DNA sequence comparison, homology and restriction site identification were performed using 
a DNA analysis software called DNA Strider. The majority of data and statistical analysis were 
performed using Prism software (GraphPad 5) using a Mann–Whitney U test.  Differences 
were found to be significant when p was less than 0.05. Kaplan-Meier day to patency curves 
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Figure 2:  Schematic representation of VIP expression vector. 
(A) The novel CASI promoter combines the cytomegalovirus (CMV) enhancer and 
chicken β-actin promoter followed by a splice donor (SD) and splice acceptor (SA) 
flanking the ubiquitin (UBC) enhancer region. (B) The VIP expression vector for 
antibody expression indicating the AAV2 inverted terminal repeats (ITR), the 
CASI promoter, an IgG1 heavy chain linked to the light chain separated by a self-
processing 2A sequence, a woodchuck hepatitis posttranscriptional regulatory 
element (WPRE) and an SV40 polyadenylation signal (SV40pA). Antibody 
variable regions of the heavy and light chains are colored in red (C) Schematic 
representation of the IgG1 transgene that was optimized for expression in vitro. 
Highlighted in blue is the human growth hormone (HGH) derived signal sequence 
(SS) and the F2A self-processing peptide (orange), yielding in separate heavy and 
light chains. Red lines mark the predicted splice donor and acceptor sites that 
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have been mutated. The Variable heavy chain (VH) is flanked by NotI and AgeI 





Figure 3: Schematic representation of 5D5 monoclonal antibody binding site on 
CSP.  
CSP consists of three main regions – a central repeat domain (grey box) bound by a 
C-Terminal region containing a type I thrombospondin repeat (TSR) motif (red box) 
and GPI anchor site (green box) on one side and an N-terminal portion containing a 
conserved proteolytic cleavage site called region I (black box) and a signal sequence 
(brown box) on the opposite side6. 5D5, an anti-P.falciparum CSP monoclonal 
antibody binds to a linear epitope EDNEKLRKPKH near the proteolytic cleavage site 







Construction and Cloning of VIP plasmids 
After decades of research, the only malaria vaccine to be licensed is the RTS, S/ASO1 in areas of 
active P.falciparum transmission38.The vaccine has an efficacy below 50% in the target 
population and the effectiveness of the vaccine wanes over time42,43. It is known that CSP 
antibodies alone can neutralize and prevent infection by sporozoites, but this requires very high 
sustained levels of antibody in the host36,44. Recently, it has been demonstrated that genes 
encoding anti – P.falciparum CSP antibodies 2A10 and 2C11 delivered to mice by a newly-
designed AAV8 vector can direct long-lived high-level mAb production. The same vaccination 
strategy has been shown to be successful against HIV in mice. This approach termed vectored 
immunoprophylaxis (VIP) is potentially applicable to any disease against which an antibody 
response alone is protective120,121. 
The positive results of the 2A10 and 2C11 VIP vector systems have encouraged the study of other 
monoclonal antibodies that may inhibit P. falciparum infection using the VIP vaccine strategy. 
5D5 is an anti-P.falciparum CSP monoclonal antibody that specifically binds to a linear epitope 
EDNEKLRKPKH near the proteolytic cleavage site in the N-terminus region of P.falciparum 
3D7 CSP, inhibiting the CSP processing122. Proteolytic cleavage of the CSP is necessary for 
parasite infection of the liver.  
Using 2A10 VIP vector plasmid as a backbone the 5D5 VH and VL chain sequences were inserted 
into the VIP vector plasmid replacing 2A10 sequences. Comparison of the VH chain sequence of 
2A10 in the VIP plasmid and 5D5 VH chain sequence revealed the presence of a signal peptide 
and cleavage site at one end and sequence homology at constant region the other end.  The same 
was noted when VL chain sequences of 2A10 in the VIP plasmid and 5D5 were compared. Signal 
peptides are important for the transport of newly synthesized proteins in the cell and mutations in 
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the signal peptide sequence can decrease the secretion efficiency of the antibody132.To avoid 
mutation of the signal peptide, The 5D5 VH and VL chains were inserted between the signal 
peptide cleavage site and sites of sequence homology between 2A10 and 5D5. The area where 
sequence homology between 2A10 and 5D5 was observed indicates the location of the constant 
region of the IgG1 chains which are highly conserved between different IgG1 antibodies133. 
Based on this information, synthetic DNA sequences encoding the 5D5 heavy and light variable 
regions, flanked by built-in restriction sites for NotI and AgeI (heavy) and NsiI and PvuII (light) 
were prepared. Clones containing the synthetic 5D5 VH and VL insert synthetic DNAs were 
digested and the VH and VL inserts were purified by electrophoresis and gel extraction. 
Restriction digestion of the backbone 2A10 VIP plasmid with Not1 and Age1 resulted in 2 bands, 
~5873bp and ~540bp. The 5873bp band was the 2A10 VIP plasmid without the 2A10 VH chain, 
and the 540bp band was the 2A10 VH chain digested out of the plasmid as predicted by DNA 
analysis software DNA Strider. Restriction digestion of the backbone 2A10 VIP plasmid with 
Nsi1 and PuvII resulted in 2 bands, ~5819bp and ~598bp. The 5819bp band was the 2A10 VIP 
plasmid without the 2A10 VL chain, and the 598bp band was the 2A10 VL chain digested out of 
the plasmid as predicted by DNA analysis software DNA Strider. No other bands were observed 
on the gel indicating the complete digestion of the backbone 2A10 VIP plasmid (not shown). The 
insert DNAs 5D5 VH and VL insert DNAs were ligated to 2A10 VIP plasmid without 2A10 VH 
chain and 2A10 VIP plasmid without 2A10 VL chain respectively to form 5D5H-2A10 Plasmid 
and 5D5L-2A10 plasmid. The correct insertion of these insert DNAs in their respective digested 
2A10 plasmids was determined by restriction digestion and sequencing. Restriction digestion of 
the 5D5H-2A10 plasmid with Nsi1 and BglII restriction enzymes resulted in 2 bands, ~5281bp 
and ~1132bp each (figure 4A). The sizes of these bands were unique to 5D5H-2A10 plasmid 
digested by Nsi1 and BglII. Restriction digestion of the 5D5L-2A10 plasmid with restriction 
enzymes DraIII and XcmI resulted in 2 bands, ~4758bp and ~1659bp. The sizes of these bands 
were unique to 5D5L-2A10 plasmid digested by DraIII and XcmI (figure 4B). The size of all the 
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bands observed on the gel were identical to the sizes predicted by DNA Strider sequence analysis 
software, indicating the correct insertion of the insert DNAs in the 2A10 VIP plasmids. 
Sequencing of the 5D5H-2A10 plasmid and 5D5L-2A10 further confirmed the correct insertion 
of the insert DNAs in the digested 2A10 plasmid.  
The 5D5 VIP plasmid was prepared using 5D5H-2A10 plasmid as the backbone. The correct 
insertion of 5D5 VL insert DNA into 5D5H-2A10 plasmid was determined by restriction 
digestion and sequencing. Restriction digestion of the 5D5 VIP Plasmid with restriction enzymes 
DraIII and XcmI resulted in 2 bands, ~4758bp and ~1659bp each (figure 4C). The size of the 
bands observed on the gel were identical to the sizes predicted by DNA analysis software DNA 
Strider, indicating the correct insertion of the insert DNAs in the 2A10 VIP plasmids. Sequencing 
of the 5D5 VIP further confirmed the correct insertion of the insert DNAs in the digested 2A10 
plasmid. The schematic diagram of b12 VIP vector transgene, 2A10 VIP Vector transgene, 
5D5L-2A10 VIP vector transgene, 5D5H-2A10 VIP vector transgene and 5D5 VIP vector 
transgene present in their respective VIP expression vectors are shown in Figure 5. 
In vitro validation of the Functionality of the 5D5 VIP plasmid  
The 5D5 VIP plasmid, 5D5H-2A10, 5D5L-2A10 and 2A10 VIP plasmids were characterized in 
vitro for human IgG antibody expression in the supernatant of transfected 293T cells (Figure 6). 
All four plasmids produced human IgG at ~0.86 μg/mL indicating no loss of function of the VIP 
plasmid after cloning. With this confirmation AAV vectors with the capsid from serotype 8 were 
made that expressed the humanized IgG mAb 5D5. 
In vivo characterization of 5D5 VIP vectors 
To determine expression by these VIP vectors in vivo, 11 C57BL/6 mice were injected 
intramuscularly in the cranial thigh muscle with 1x10
11  
genome copies (GC) of 5D5-AAV, b12-
AAV (AAV expressing HIV mAb b12, Baltimore lab) or media alone. Within one week post 
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transduction, all AAV-transduced mice expressed between 100-200 µg/mL of human IgG 
antibodies. Expression continued to increase till 3 weeks post transduction and was sustained out 
to 6 weeks (Figure 7A). The antibody concentration was maintained between 800-1000 μg/mL in 
all mice. To ensure that the initial manipulation of the CSP-specific mAb did not affect their 
ability to bind to CSP, sera from transduced mice were used to probe recombinant CSP by ELIZA 
(Figure 7B). 5D5 transduced mice expressed antibodies that bound to recombinant CSP with 
similar kinetics as human IgG antibody expression (Figure 7B). Sera from b12-AAV mice and 
media alone mice did not recognize recombinant CSP, demonstrating the specificity of the 5D5 
antibody. 
Pb-PfCSP Challenge 
To test the ability of VIP to protect mice from challenge in vivo, 1.0x10
4 
Pb-PfCSP sporozoites 
isolated from infected Anopheles stephensi mosquitoes were injected i.v. into the tail vein of 20 
mice six weeks post transduction with 5D5-AAv or b12-AAV vectors. Antibodies specific for 
CSP block liver invasion by sporozoites.  Therefore, mice were sacrificed 38.5h post infection, a 
time when viable sporozoites will have successfully invaded and replicated in liver cells. RNA 
was extracted from liver homogenates, followed by cDNA synthesis and finally qPCR was used 
to quantify the P. berghei 18S rRNA copies in the liver to reflect the parasite burden. In two 
independent experiments, 5D5 mice had a statistically significant reduction in parasite burden as 
compared to b12-AAV mice (data for one experiment is shown in Figure 8). 
In the mosquito bite challenge experiment, the infectivity of the mosquito cage was estimated to 
be 80 % by dissecting a limited number of salivary glands (n=10) and checking for the presence 
of sporozoites. 4-5 mosquitoes fed on each 5D5-AAV and b12-AAV transduced mouse. This 
was determined by dissecting the midgut to check for blood.  4 days post challenge, blood stage 
parasitemia was observed in all b12-AAV and 5D5 transduced mice (Figure 9B). All the mice 
challenged in this experiment had 700-1000 μg/mL of human IgG in their sera (Figure 9A). The 
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experiment was repeated and the same results were noted again. 
 
Luciferase assay to detect neutralizing antibodies against AAV   
Pre-existing neutralizing anti-AAV antibodies and acquired antibodies generated after treatment 
with rAAVs  can reduce or inhibit the efficiency of AAV vectored therapeutics, especially if the 
vector need to administered repeatedly103,104.  
Four Aotus monkeys referred to as A304, A336, A312 and A247 were transduced with an AAV 
vector expressing 2A10. A304 and A336 were transduced with 2A10-AAV1. A312 and A247 
were transduced with 2A10-AAV8 and 6 months later they were transduced again with 2A10-
AAV7.The monkey serums were tested for vector-encoded anti-CSP antibody expression by 
ELISA done by Dr. Gary Ketner. A304 transduced with AAV1 expressing 2A10, produced anti-
CSP antibodies up to 15 weeks post transduction (Figure 10A). The other 2A10-AAV1-
transduced monkey, A336, showed low levels of anti-CSP until week three after which the anti-
CSP antibody expression declined until it was no longer detectable (Figure 10A). Anti-CSP 
antibodies present in the sera of Aotus monkeys 312 and 247 transduced with AAV8 expressing 
2A10 mAb expressed anti –CSP antibodies at varying amounts until no anti-CSP antibodies were 
detected 7 weeks post transduction (Figure 11A). A312 had peak levels of anti-CSP antibodies at 
week 2 after which the antibody levels declined (Figure 11A). Anti-CSP antibodies levels peaked 
at week 5 for A247 after which it declined (Figure 11A).  Aotus monkeys 312 and 247 transduced 
with 2A10-AAV7, 6 months post transduction with AAV8 did not express detectable levels of 
anti– CSP antibodies (Figure 12A). One hypothesis for the failure to express 2A10 mAb in some 
of the Aotus is that the presence of pre-existing anti-AAV neutralizing antibodies against the 
AAV vectors, inhibited the efficient transduction of the vector.  
To investigate that possibility, an assay was developed to detect anti-AAV neutralizing antibodies 
against different AAV serotypes using vectors expressing luciferase. The sera of A304 and A336 
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before and after immunization with 2A10-AAV1 was tested and A304 pre-bleed had lower 
neutralizing activity compared to A336. A336 showed 90% neutralizing activity up to dilution 
1:1000 (Figure 10B) and A304 showed 90% neutralizing activity up to dilution 1:316 (Figure 
10B). After immunization with 2A10-AAV1 the neutralizing activity of A304 increased and the 
neutralization percentage did not fall below 90% even at the 1:3160 dilution (highest dilution) 
(Figure 10B). A336 showed a slight increase in neutralizing activity as well, post 2A10-AAV1 
transduction (Figure 10B).  
The sera of A312 and A247 before and after immunization with 2A10- AAV8 were tested for 
anti-AAV8 neutralizing antibodies (Figure 11B). Pre-bleeds of both A312 and A247 monkeys 
that were administered had neutralizing activity below 40% at 1:10 dilution which increased after 
immunization with 2A10-AAV8 to above 95% (Figure 11B). The neutralizing activity against 
AAV8 increased further in both monkeys after immunization with 2A10-AAV7 (6 months post 
2A10-AAV8 transduction) which can be observed in the higher dilutions (1:100 to 1:3160) 
(Figure 11B). The sera of A312 and A247 before and after immunization with 2A10-AAV7 were 
tested for anti-AAV7 neutralizing antibodies (Figure 12B). Pre-bleeds of both monkeys had high 
neutralizing activity (above 90%) (Figure 12B). Immunization with 2A10-AAV8 (6 months 
before 2A10-AAV7 transduction) did not change the neutralizing percentage against AAV7 in 
either monkey (Figure 12B). However, neutralizing activity against AAV7 increased in both 
monkeys post 2A10-AAV7 immunization (Figure 12B). These results seem to confirm the 
hypothesis that anti-AAV antibodies inhibit 2A10-AAV expression and the need to pre-screening 
animals for pre-existing anti-AAV antibodies before VIP administration. Pre-bleeds sera from ten 
Aotus monkeys were obtained prior to selection of the four Aotus described above.  These sera 
were diluted to 1:316 and were screened for neutralizing antibodies against AAV1, -8 and -7 
(Figure 13).The cutoff neutralization value above which no VIP expression would occur was 
estimated to be 90% based on the 2A10-AAV1 neutralizing antibody experiments mentioned 
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previously. Out of the ten monkeys, only A336 had a neutralizing activity above 90% against 
AAV1. All ten monkeys had neutralizing activity below 90% against AAV8 (Figure 13), 
suggesting that the 90% cutoff may be too high for AAV8. Four of the ten monkeys had 





             
                                                                                                                                                                                                                                                             
            
Figure 4: Confirmation of 5D5H-2A10, 5D5L-2A10 and 5D5 VIP plasmid clones by 
restriction digestion. 
Restriction digestion of (A) 5D5H-2A10, (B) 5D5L-2A10 and (C) 5D5 VIP plasmid at unique 
restriction sites to confirm the correct insertion of 5D5 VH and VL chains in the 2A10 VIP 





5281bp and 1132bp each. Restriction digestion of 5D5L-2A10 plasmid with DraIII and XcmI 
resulted in 2 bands, 4758bp and 1659bp. Restriction digestion of the 5D5 VIP Plasmid with 
DraIII and XcmI resulted in a 2 bands, 4758bp and 1659bp.These bands match the sizes predicted 
























Figure 5: Schematic representation of b12 transgene, 2A10 transgene, 5D5H-2A10 
transgene, 5D5L-2A10 transgene and 5D5 transgene in VIP expression vector. 
A Transgene cassette in VIP expression vector containing b12 variable regions (grey boxes) 
called b12 VIP vector was prepared by David Baltimore’s Laboratory. VIP vectors with this 
transgene express b12 monoclonal Antibody (mAb), an anti-HIV-1 mAb. (B) Transgene cassette 
in VIP expression vector containing 2A10 variable regions (yellow boxes) called 2A10 VIP 
vector was prepared by David Baltimore’s Laboratory. VIP vectors with this transgene express 
2A10 mAb that binds to the central repeat region of P.falciparum CSP36. (C) Transgene cassette 
in VIP expression vector containing 2A10 variable heavy (VH) chain (yellow box) and 5D5 
variable light (VL) chain (green box) called 5D5L-2A10 VIP vector was prepared by replacing the 
2A10 VL chain with 5D5 VL chain in 2A10 VIP vector. (D) Transgene cassette in VIP expression 
vector containing 5D5 VH chain (green box) and 2A10 VL chain (yellow box) called 5D5H-2A10 
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VIP vector was prepared by replacing the 2A10 VH chain with 5D5 VH chain in 2A10 VIP vector. 
Transgene cassette in VIP expression vector containing 5D5 variable regions (green boxes) called 
5D5 VIP vector was prepared by replacing the 2A10 VL chain with 5D5 VL chain in 5D5H-2A10 
VIP vector. VIP vectors with this transgene express 5D5 mAb that binds to N-terminus region 






Figure 6: Cloned VIP plasmids expressing high quantity of human IgG antibodies in 
vitro. 
The expression activity of each plasmid was tested in vitro by transfecting 293T cells with 2A10 
VIP plasmid, 5D5 VIP plasmid, 5D5H-2A10 plasmid and 5D5L-2A10 plasmid. Supernatant from 
transfected cells was assayed for human IgG 48h post transfection by ELISA. The amount of the 






































Figure 7: 5D5-AAV8 expresses high levels of sustained human IgG antibody in vivo, 
and VIP- produced Plasmodium falciparum antibodies retain ability to recognize 
CSP. 
Quantification of human IgG (A) and anti-CSP antibodies (B) by ELISA after intramuscular 
injection of 1x10
11 
genome copies of the VIP expression vector producing b12 and 5D5 in 
female C57BL/6. The plot shows mean and standard error of titers for each mouse, n=4 or 3 for 
media injected mice. All vectors express high levels of sustained human IgG antibody in vivo, 















Six weeks post b12-AAV8 (anti-HIV-1 mAb expressing VIP system) and 5D5-AAV8 (anti-P 
falciparum CSP mAb expressing VIP system) administration, mice were challenged 
intravenously with 1.0x10
4 
Pb-PfCSP sporozoites. Mouse liver was extracted 38.5 hours post 
challenge and qPCR for P. berghei 18S rRNA copies was done to determine parasite burden. 
The plot shows values for each individual mouse and the mean of the group (n=10 or 5 for 
uninfected). VIP administration significantly reduces parasite burden in the liver (*** When p 
value ≤ 0.001)









A) Concentration of human IgG in serum samples of mice transduced with 5D5-AAV and 
b12-AAV measured by ELISA, 6 weeks post transduction. Mice that received 5D5-AAV or 
b12-AVV challenged with Pb-PfCSP sporozoites delivered by infected mosquito bite, 6 weeks 
post-transduction. The Kaplan-Meier curve depicts percentage of mice that were parasite-free, 
determined by monitoring mice for the presence of blood-stage parasites in blood smears taken 
daily beginning at 4 days post challenge (n=10). 5D5-AAV transduced mice did not show 
delayed parasitemia compared to the b12-AAV group.






Figure 10: Neutralizing antibody titers against AAV1 affect the expression of VIP in 
Aotus monkeys. 
(A) Anti-CSP antibodies present in the sera of Aotus monkey 304 and 336 transduced with 
AAV1 expressing 2A10 mAb was detected by ELISA, done by Dr. Gary Ketner. A304 expressed 
2A10 mAb over 15 weeks post transduction, however  A336 expressed  2A10 mAb until week 
three after which no anti- CSP antibody was detected. (B) Presence of neutralizing antibodies 
against the AAV1 in pre-bleed and after immunization with 2A10-AAV1 monkey sera was 
determined. A304 P.B that expressed 2A10 mAb had a lower titer of neutralizing antibodies 
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Figure 11: VIP mAb expressed for a short period in Aotus monkeys having low 
neutralizing activity against AAV8. 
A) Anti-CSP antibodies present in the sera of Aotus monkey 312 and 247 transduced 
with AAV8 expressing 2A10 mAb was detected by ELISA, done by Dr. Gary Ketner. 
Both A312 and A247 expressed anti– CSP antibodies at varying amounts until no 














































P.B A312 A312 After immunisation with AAV8
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neutralizing antibodies against AAV8 in pre-bleed, after immunization with 2A10-
AAV8 and 2A10-AAV7 monkey sera were determined. Pre-bleeds of both monkeys 
had neutralizing activity (below 40%) that increased after immunization with 2A10-
AAV8.The neutralizing activity against AAV8 monkeys increased further in both 







Figure 12: High neutralization activity against AAV7 inhibits the expression of VIP 
mAb in Aotus monkeys. 
A) Anti-CSP antibodies present in the sera of Aotus monkey 312 and 336 transduced with 2A10-
AAV7 expressing 2A10 mAb was detected by ELISA, done by Dr. Gary Ketner. Both A312 and 
A247 did not expressed any anti– CSP antibodies. B) Presence of neutralizing antibodies against 













































P.B A 312 A312 After immunisation with AAV8
A312 after immunisation with AAV7 P.B M 247
A247 After immunisation with AAV8 A247 After immunisation with AAV7
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AAV7 monkey sera were determined. Pre-bleeds of both monkeys had high neutralizing activity 
(above 90%). Immunization with 2A10-AAV8 did not change the neutralizing percentage against 






Figure 13: Pre-screening of ten Aotus monkey sera for anti-AAV neutralizing 
antibodies against AAV1, -8 and -7. 
Pre-bleeds sera of ten Aotus monkeys were diluted to 1:316 and were screened for neutralizing 
antibodies against AAV1, -8 and -7 .The cutoff neutralization value above which no VIP 
expression would occur was estimated to be 90% based on the 2A10-AAV1 neutralizing antibody 
experiments mentioned previously. Out of the ten monkeys, only A336 had a neutralizing activity 
above 90% against AAV1.All ten monkeys had neutralizing activity below 90% against AAV8. 
Four of the ten monkeys had neutralizing activity above 90% against AAV7 (A304, A312, A418 
and A247). Pre-bleeds of ten Aotus monkeys were screened for neutralizing antibodies against 






































Despite tremendous efforts, malaria remains a major global health problem with over 3.2 billion 
people still at risk from this parasitic disease1. The WHO estimates that there were 214 million 
cases of malaria in 2015 and 438,000 deaths1. The only malaria vaccine licensed is the RTS, 
S/AS01 which targets the human malarial parasite P.falciparum. RTS, S is a pre-erythrocytic 
malaria vaccine that consists of a hepatitis B surface antigen (HBsAg) fused to 19 copies of the 
central repeat region and  C-terminal flanking region of P. falciparum incorporated into a virus-
like particle  with unfused HBsAg, which induces an immune response against CSP 39. The 
vaccine efficacy of RTS, S was found to be below 50% and the protection it offers wanes over 
time42. Naturally acquired immunity develops in populations in areas where transmission is 
sustained but this immunity develops slowly and does not yield in sterile protection134. The only 
strategy that consistently provides sterile protection is vaccination with radiation-attenuated 
sporozoites, which is not clinically feasible in areas of high malaria burden as it requires bites by 
multiple infected irradiated mosquitoes or at least five intravenous injections with irradiated 
sporozoites19,28. Therefore, a different approach needs to be taken in the development of vaccines 
against malaria. 
It has been known for a long time that antibodies targeting CSP can prevent malaria infection by 
inhibiting sporozoites from invading liver cells36,44. However for sterile protection, all sporozoites 
need to be neutralized before they reaches the liver of the host. A single sporozoite successful in 
invading the liver can cause disease. David Baltimore’s laboratory at California Institute of 
Technology developed a way to express high titer monoclonal human IgG antibodies in vivo by 
using an AAV vector, which is termed Vectored immunoprophylaxis (VIP). Humanized mice 
vaccinated using this approach were protected against HIV, and immune deficient mice were 
protected against a lethal influenza challenge, demonstrating the effectiveness of this technology 
in protecting against infectious diseases where antibody alone is protective 120,121. Gary Ketner’s 
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laboratory at Johns Hopkins Bloomberg School of public health characterized an AAV8 vector 
expressing humanized monoclonal anti-P.falciparum CSP antibodies 2A10 or 2C11. The mice 
that were transduced with 2A10-AAV and 2C11-AAV expressed high levels of human IgG, and 
these antibody levels were maintained over 52 weeks45. Mice expressing these mAbs showed a 
significant decrease in liver parasite burden after i.v tail vein challenge with transgenic Pb/Pf  P. 
berghei parasites expressing CSP bearing the P. falciparum central repeat region45. 60% of 2A10-
AAV and 30% of 2C11-AAV transduced mice showed sterile protection and the other mice in 
these groups showed delayed parasitemia compared to the control group when challenged by 
infected Pb/Pf mosquito bites45. The successful use of the VIP system against malaria has 
motivated further research to characterize other mAb expressing VIP systems. 
5D5 is an anti- P.falciparum CSP monoclonal antibody that specifically binds to a linear epitope 
EDNEKLRKPKH in the N-terminus region of P.falciparum 3D7 CSP, inhibiting the CSP 
processing122, an essential process for the invasion of  the liver by sporozoites while the 
previously characterized 2A10 mAb and 2C11 mAb bind to the central repeat region of 
P.falciparum CSP122. The 5D5 variable regions were cloned into the 2A10 VIP expression vector, 
replacing the 2A10 variable region sequences. Two intermediate VIP expression vectors, 5D5H-
2A10 and 5D5L-2A10 were formed in the process. The amount of human immunoglobulin G 
(hIgG) produced by the 5D5 VIP plasmid and the intermediate plasmids were compared to the 
amount of hIgG produced by the original 2A10 VIP plasmid. All the plasmids produced similar 
amounts of human IgG (~0.86 μg/mL) indicating that the cloning of 5D5 variable chain 
sequences into the VIP plasmids did not affect the functionality of the plasmid. The functional 
5D5 VIP plasmid was used to make an AAV8 vector virus expressing 5D5 mAb as previously 
described120. 
In vivo studies of AAV8 expressing 5D5 in mice, resulted in mAb expression at ~100-1000 
µg/mL of human IgG, as early as one week post transduction. The levels of human IgG 
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increased until 3 weeks post transduction and then was maintained at 800-1000 μg/mL until the 
end of the study (6 weeks). These levels of human IgG post VIP administration are similar to 
that produced by 2A10-AAV 45. The expressed 5D5 mAbs recognized recombinant CSP which 
further supports the conclusion that manipulation and cloning of 5D5 sequence into the VIP 
plasmid did not affect the functionality of the mAb. Mice transduced with 5D5-AAV expressing 
hIgG levels between 700-1000 μg/mL showed a statistically significant reduction in liver 
parasite burden following i.v. Pb/PfCSP sporozoite challenge. The mice are sacrificed in this 
experiment 48h after i.v. Pb/PfCSP sporozoite challenge to extract their livers and delay to 
patency cannot be observed.  When challenged by infected Pb/PfCSP mosquito bites, a more 
natural route of infection, no delay to patency and no sterile protection was observed in the 5D5 
transduced mice expressing hIgG levels between 700-1000 μg/mL. This suggest that though 
5D5 mAb effectively decreases the liver parasite burden, the decrease in liver parasite burden 
may not be sufficient to cause delay to patency in the mosquito bite challenge as the liver stage 
and the erythrocytic stage of the parasite are multiplication stage in the life cycle of the parasite. 
It is also of note that the use of synthetic humanized DNA sequences of the variable regions of 
the 5D5 mAb and the insertion of these variable region sequences into the VIP expression 
plasmid may have decreased the avidity of the 5D5 monoclonal antibody.  
For sterile protection against P.falciparum infection, all mosquito inoculated sporozoites need to 
be neutralized before they invade the liver. This requires sustained high levels of mAb in the 
host which is possible by VIP system. Optimization of this vaccine may provide sterile 
protection. Optimization of this method includes the use of other pre-erythrocytic monoclonal 
antibodies with a greater protective capacity or the use of a combination of mAbs that target 
different binding sites in the CSP or bind to a completely different antigens in the pre-
erythrocytic that may work synergistically to have a greater protective effect. While this 
particular study only utilized mAb targeting the N-terminus region of CSP, multiple stages of 
the parasite could easily be targeted at once via different mAb. The potential for this technology 
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is limitless and multiple approaches can be taken to optimize it as a form of malaria control. 
An obstacle to the use of AAV for therapeutics is the presence of pre-existing neutralizing anti-
AAV antibodies and acquired antibodies generated after treatment with rAAVs that can reduce or 
inhibit the efficiency of these therapeutics, especially if the vector needs to administered 
repeatedly103,104. Around 30-80% of the world’s population is estimated to be seropositive for 
antibodies against AAV serotypes 1 and 2, with anti-AAV2 being the most prevalent105. The 
development of this humoral response to AAV is thought to occur early in life around at the age 
of two as a consequence of WT AAV exposure 108,109. Additionally, new born babies have been 
found to have maternal anti-AAV antibodies that decrease few months after birth but increase 
again 108,109. These studies show that the time frame where individuals are naïve to Anti-AAV is 
narrow, making it difficult to administer AAV vectored therapeutics. In contrast to humans, 
AAV7, AAV8, AAV9, and AAVrh10 are the most seroprevalent AAV serotypes in non-human 
primates135–137 and AAV2 has the lowest seroprevalence138. The prevalence of neutralizing anti-
AAV antibodies in non-human primates puts forth a challenge to evaluate the performance of 
AAV vectored therapeutics.  
In experiments to test the expression of 2A10 mAb by VIP in a non-human primate (NHP) that 
provides a P. falciparum challenge model, four Aotus monkeys - A304, A336, A312, and A247 
were transduced with AAV vector expressing 2A10 mAb. A304 and A336 were transduced with 
2A10-AAV1. A312 and A247 were transduced with 2A10-AAV8 and six months later they were 
transduced with 2A10-AAV7. The monkey sera were tested for anti-CSP antibody expression by 
ELISA, done by Dr. Gary Ketner. A304 transduced with 2A10-AAV1 expressed anti-CSP 
through the end of the experiment at fifteen weeks post transduction. The other monkey A336 
showed brief anti- CSP antibody expression till week three after which the anti-CSP antibody 
expression declined until it was no longer detectable. Both A312 and A336 transduced with 
2A10-AAV8 expressed anti-CSP antibodies for a brief time while A312 and A336 transduced 
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with 2A10-AAV7 six months after 2A10-AAV8 transduction did not express detectable levels of 
anti-CSP antibodies. From these results the vector that best expressed 2A10 by VIP was AVV1 
(A304) in non-human primates. AAV8 failed to express AAV8 over long periods of time and 
AAV7 is extremely seroprevalent in non-human primates135–137. 
 By testing the pre-bleed sera of the monkeys (A304, A336, A312 and A247) for neutralizing 
anti-AAV antibodies, we concluded that pre-existing anti-AAV neutralizing antibodies may play 
a role in the effectiveness of AAV vectored mAb expression in the NPH models.  In particular, in 
monkeys A304 and A336 transduced with 2A10-AAV1, higher neutralizing anti-AAV1 
antibodies levels in A336 pre-bleed sera compared to A304 pre-bleed sera may account for the 
differences in AAV1-driven antibody synthesis. It was also noted anti-AAV1 antibody titer 
increased in both monkeys post 2A10-AAV1 administration which may pose a problem for the 
re-administration of the vaccine using the same vector in the same subjects. Similarly, the 
successful expression of anti-CSP antibodies few weeks after 2A10-AAV8 transduction in A312 
and A247, may reflect the low titer of neutralizing anti-AAV8 antibodies in both monkey pre-
bleeds and the titer of neutralizing anti-AAV8 antibodies increased post 2A10-AAV8 
transduction and 2A10-AAV7 transduction. Pre-bleeds of A312 monkeys had high neutralizing 
activity against AAV7 which may explain that lack of 2A10 expression in these monkeys. 
Immunization with 2A10- AAV8 (6 months before 2A10-AAV7 transduction) did not change the 
neutralizing percentage against AAV7 in both monkeys. However, neutralizing activity against 
AAV7 increased in both monkeys post 2A10-AAV7 immunization. 
Neutralizing anti-AAV antibodies do pose a major obstacle to the use of AAV as a vector for 
therapeutics but due to the extensive use and advantages of AAV as vector; many strategies have 
been developed to overcome this problem. This includes the pre-screening of subjects for pre-
existing anti-AAV antibodies, development of novel, artificial AAV vectors113, plasmapheresis114, 
transient immunosuppression115,116, delivery of the vector with isolated perfusion and saline 
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flushing117 and modulation of antibody responses with empty capsids118. Recently, a group of 
scientists used phylogenetic analysis to reconstruct an ancestral strain of AAV called Anc80L65. 
Anc80L65 is not neutralized by sera from mice immunized with several commonly-used AAV 
types139. Gene delivery through Anc80L65 has been shown to be successful in both mice and 
non-human primate models139 and may prove to be a good vector for VIP method of vaccination. 
Other immune responses like cytotoxic T lymphocyte responses against the vector may also 
effect the efficiency of transgene expression140. Studies have demonstrated that the activation of T 
cells against the vector capsid is limited to serotypes that have a heparin binding motif and exhibit 
heparin-binding activity141. Interestingly, serotypes such as AAV8 that lack this activity are better 
tolerated in vivo since they do not induce cytotoxic T lymphocyte responses, making it more 
likely that long term transduction will be achieved141. AAV vectored therapeutics administered at 
a low doses or into an immunoprivileged site have successfully expressed the transgene without 
the induction of a strong immune response against the vector142,143. 
AAV vectors have been utilized for many years in both vaccine and gene therapy trials and have 
exhibited a good safety record. However, safety concerns still exist and a major concern centers 
on the ability of WT AAV to integrate into host DNA. In vitro studies have shown that WT AAV 
integrates in a site-specific manner on the chromosome 19q13.42 (AAVS1)79,80, chromosome 
5p13.3 (AAVS2) and chromosome 3p24.3 (AAVS3) 82. This site-specific integration of WT AAV 
in AAVS1 is rep dependent81, and rep is not present in rAAV used for gene therapy and other 
therapeutics. In vivo studies have shown the WT AAV DNA integrates at a low frequency and 
majority of the DNA exists as double stranded episomes in human tissue83. rAAV lacks many 
components of WT AAV but are still found to integrate into the host genome at a low frequency 
which can potentially lead to genotoxicity84. A recent study done to test the safety and site-
specific integration of rAAV vectors using the EMA licensed AAV1-LPLS447X vector which was 
developed for the treatment of lipoprotein lipase deficiency (LPLD) showed that rAAV vector 
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integration was infrequent, mainly occurred within a nuclear mitochondrial DNA region (Similar 
sequences present in both mitochondrial and nuclear genomes 86. The results also showed no 
significant vector genome integration in the AAVS1 locus or the AAV-HCC locus (implicated in 
AAV integration–mediated formation of hepatocellular carcinoma)86, further supporting the 
safety of rAAV and their use as a vector for therapeutics and vaccination strategies. 
Despite decades of research, the only malaria vaccine to be licensed is RTS, S/AS01. This 
vaccine cannot be used in the fight to eradicate malaria as it has a low efficacy and does not 
protect for a long period of time42. Research is ongoing to develop second-generation vaccines. 
Given the disease burden caused by malaria and the importance of eradicating it, novel vaccine 
approaches need to be explored as well. Our work demonstrates the feasibility of using a viral 
vector to express broadly neutralizing antibodies against malaria at high titers for a sustained 
period of time. With optimization of this strategy, VIP could be used in endemic areas as 
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 Completed six months rotation in the Sinnis lab where the main focus is on the skin stage 
of malarial parasites. My rotation project’s main goal was to study the effects of an 
antibody 2F6 on Plasmodium yoelii liver load in vivo. 2F6 is thought to bind at the repeat 
region of the Circumsporozoite protein of P.yoelii and inhibit the sporozoites from 
entering the blood vessels and in turn the liver. 
 Studied the process to purify antibody from ascites and did some initial experiments to 
study the half-life of 2F6. Worked on mosquitoes and mice during lab rotations.  
 Decided to carry out thesis project in the Ketner lab that is currently working on a 
vectored immunoprophylaxis against Plasmodium falciparum infection. The vector, in 
this case, is adeno-associated virus and it delivers anti-P. falciparum monoclonal 
antibody genes, which act on the Circumsporozoite protein of the sporozoite preventing 
further progression of the malarial parasite life cycle in the host. Through this project, I 




 Currently working on a luciferase assay to detect the presence of neutralizing antibodies 
against the vector before immunization with this treatment as a side project. The presence 
of the neutralizing antibodies may play a role in the effectiveness of this treatment and it 
could also help in deciding which vector should be used for immunization. 
 Performed and asserted responsibilities of a teaching assistant in the course introduction 
to biomedical sciences both for the online and onsite version. Graded and discussed class 
materials in the context of real-world problems (online version) and conducted 2 lectures 
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Serratia marcescens VITSD2: A strain producing optimum serratiopeptidase” and was 
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